This content was funded by Sanofi.
In this video, learn about what is new and important in the treatment of immune thrombocytopaenia, with a focus on patient perspectives and unmet clinical needs.
Chapters:
- 00:00–02:20 – Introduction (David J. Kuter, USA [Chair])
- 02:45–21:50 – What are the Key Clinical Concerns When Choosing Treatment? (Waleed Ghanima, Norway)
- 22:15–37:00 – How to Navigate Patient Concerns with Clinical Outcomes (Cindy Neunert, USA)
- 37:05–59:00 – Can Emerging Treatments Help Fill the Gaps? (David J. Kuter, USA)
- 59:05–1:13:05 – Closing and Q&A (All faculty – moderated by Chair)
Speakers:
Waleed Ghanima1
David J.Kuter2
Cindy Neunert3
1. Head of Research and Consultant Haematologist, Østfold Hospital; and Professor at the Institute of Clinical Medicine, University of Oslo, Norway. Ghanima is a Principal Investigator in the Phase 3 rilzabrutinib study, LUNA 3.
2. Program Director of Hematology, Massachusetts General Hospital; and Professor of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
3. Associate Professor of Pediatrics, Columbia University Irving Medical Center, New York, USA. Neunert received fellowship training in Pediatric Hematology-Oncology at the University of Texas Southwestern Medical School, Dallas, Texas, USA, where she also obtained her master’s degree in clinical research.
| Read more here |
